PURPOSE: A national primary and secondary healthcare-level study in the Czech Republic has not yet been conducted to evaluate the prevalence of migraine. We analyzed the current treatment patterns (acute and prophylactic) in migraine patients and the number of migraine patients potentially eligible for treatment with recent calcitonin gene-related peptide (CGRP) pathway-targeted therapies. METHODS: This retrospective study utilized the Ministry of the Interior Health Insurance Fund claims database of the Czech Republic wherein every citizen is insured. Migraine patients with or without aura, and potentially on triptan therapy were included in this study (index years 2012-2016). The prevalence approach included all patients (new and old) present in each index year. Prophylactic therapies were followed f0or three and seven years prior to the index year, including the index year, until 2010. The incidence approach included all patients first diagnosed in each index year. Prophylactic therapies were followed for the next three years, including the index year, until 2017 following incidence approach. The primary endpoint of this study was to determine the rate of migraine prevalence and diagnosis for each index year during the period 2012-2016. The study also evaluated prophylactic and acute treatment patterns and comorbidities among patients in 2016. RESULTS: The rate of migraine prevalence was 1% and the rate of diagnosis was 0.2-0.4%. By prevalence approach, approximately 39% of the patients were on prophylactics, and 11.2% and 21.6% of the patient population had two prior treatment failures (three- and seven-year recall period, respectively). Antiepileptics (26%) and beta blockers (15.8%) were the most prescribed prophylactics, and sumatriptan was the predominant triptan used (12%) for acute treatment. CONCLUSION: Taking into account the number of inhabitants in the Czech Republic (10.7 million), there could be up to 23,000 adult patients eligible for novel CGRP therapies.

Aixial s r o Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Pharmacy Department of Social and Clinical Pharmacy Charles University Prague Prague Czech Republic

International Clinical Research Center St Anne's University Hospital Brno Brno Czech Republic

Novartis s r o Prague Czech Republic

Prague Headache Center DADO MEDICAL s r o Prague Czech Republic

University Thomayer Hospital Prague Czech Republic

Zobrazit více v PubMed

GBD Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–480. PubMed PMC

Stovner LJ, Nichols E, Steiner TJ; GBD Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976. doi:10.1016/S1474-4422(18)30322-3 PubMed DOI PMC

Reuter U. GBD 2016: still no improvement in the burden of migraine. Lancet Neurol. 2018;17(11):929–930. doi:10.1016/S1474-4422(18)30360-0 PubMed DOI

American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18. PubMed

Vargas BB. Acute treatment of migraine. Continuum (Minneap Minn). 2018;24(4, Headache):1032–1051. PubMed

Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn). 2018;24(4, Headache):1052–1065. PubMed

Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4Headache):973–989. PubMed PMC

Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121–130. PubMed

Lattanzi S, Brigo F, Trinka E, et al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79(4):417–431. doi:10.1007/s40265-019-01069-1 PubMed DOI

Han L, Liu Y, Xiong H, Hong P. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 2019;9(2):e01215. doi:10.1002/brb3.1215 PubMed DOI PMC

Wang SJ, Chen PK, Fuh JL. Comorbidities of migraine. Front Neurol. 2010;1:16. PubMed PMC

Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361–378. PubMed PMC

Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703–711. PubMed

Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115. doi:10.1186/s10194-018-0946-z PubMed DOI PMC

Vo P, Paris N, Bilitou A, et al. Burden of migraine in Europe using self-reported digital diary data from the migraine Buddy(c) application. Neurol Ther. 2018;7(2):321–332. PubMed PMC

Wu C-S, Lai M-S, Gau SS-F, Wang S-C, Tsai H-J. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PLoS One. 2014;9(12):e112257. doi:10.1371/journal.pone.0112257 PubMed DOI PMC

Neubauer S, Kreis K, Klora M, Zeidler J. Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ. 2017;18(5):533–536. doi:10.1007/s10198-016-0849-3 PubMed DOI

Pavlovic JM, Yu JS, Silberstein SD, et al. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia. 2019;39(4):465–476. PubMed PMC

Czech Statistical Office. Public database CZSO 2019. Available from: https://www.czso.cz/csu/czso/population. Accessed December10, 2019.

Lucas C, Pozo Rosich P, Watson D, et al. A real-world analysis of the burden of migraine in patients with prior treatment failures: evidence from the become study. J Headache Pain. 2019;20(1):109. PubMed

Borsook D, Dodick DW. Taking the headache out of migraine. Neurol Clin Pract. 2015;5(4):317–325. doi:10.1212/CPJ.0000000000000171 PubMed DOI PMC

Sokolovic E, Riederer F, Szucs T, Agosti R, Sándor PS. Self-reported headache among the employees of a Swiss university hospital: prevalence, disability, current treatment, and economic impact. J Headache Pain. 2013;14(1):29. doi:10.1186/1129-2377-14-29 PubMed DOI PMC

World Health Organization. Headache disorders 2016. World Health Organization; Available from: https://www.who.int/news-room/fact-sheets/detail/headache-disorders. Accessed December30, 2019.

Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. PubMed

Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. PubMed PMC

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:Cd010610. PubMed PMC

Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi:10.1186/s10194-018-0955-y PubMed DOI PMC

Smelt AF, Assendelft WJ, van Dijk CE, Blom JW. Triptan use after starting prophylactic migraine treatment: a retrospective cohort study in a primary care population. Cephalalgia. 2014;34(11):927–932. doi:10.1177/0333102414521511 PubMed DOI